Therapy: AP-SA02.
Indication: Adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus (MSSA) or methicillin resistant S. aureus (MRSA).
Armata is committed to developing safe and effective medicines to transform the lives of patients with serious or life-threatening bacterial infections. Our goal is to provide access to our investigational drugs at the appropriate time and in the safest manner for patients. We are currently developing multiple products to combat multidrug-resistant bacterial infections. The route to marketing approval for investigational drugs requires conducting multiple clinical trials. Armata believes that participation in one of our clinical trials is the most appropriate way to access our investigational drug. Armata considers requests for expanded access on a case-by-case basis. This approach preserves FDA oversight of expanded access, patient safety, and the integrity of clinical trials.